<DOC>
	<DOCNO>NCT02877212</DOCNO>
	<brief_summary>Idiopathic thrombocytopenic purpura ( ITP ) autoimmune disease characterize antibody-mediated platelet destruction . The complex pathogenesis ITP multiple challenge immune system term genetic predisposition , infection , responsiveness immunosuppressive therapy ( IST ) inhibition platelet production proven diversity constraint diagnose treat ITP . Thrombopoietin receptor agonist ( Eltrombopag ) specifically indicate treatment thrombocytopenia patient chronic immune ( idiopathic ) thrombocytopenic purpura ( ITP ) insufficient response corticosteroid , immunoglobulin , splenectomy . This clinical trial aim investigate association Fc gammaRIIIA gene ( V158F ) genetic predisposition treatment outcome Immune Thrombocytopenia ( ITP ) refractory ITP patient especially Eltrombopag .</brief_summary>
	<brief_title>Association FcγRIIIA Polymorphism THPO Expression With Response Eltrombopag Refractory ITP Patients</brief_title>
	<detailed_description>Immune thrombocytopenic purpura ( ITP ) autoimmune disorder decrease number circulate platelet ( thrombocytopenia ) manifest bleed tendency , easy bruising ( purpura ) , extravasation blood capillary skin mucous membrane ( petechia ) . In person ITP , platelet coat autoantibody platelet membrane antigen , result splenic sequestration phagocytosis mononuclear macrophage . The result shortened life span platelet circulation , together incomplete compensation increase platelet production bone marrow megakaryocyte , result decrease platelet count . In immune thrombocytopenic purpura ( ITP ) , abnormal autoantibody , usually immunoglobulin G ( IgG ) specificity one platelet membrane glycoprotein ( GPs ) , bind circulate platelet membrane induce clinically significant platelet dysfunction directly block access agonist platelet Gp receptor . Autoantibody-coated platelet induce Fc receptor-mediated phagocytosis mononuclear macrophage , primarily exclusively spleen . The spleen key organ pathophysiology ITP , platelet autoantibody form white pulp , also mononuclear macrophage red pulp destroy immunoglobulin-coated platelet . Polymorphisms FcγRIIIA implicate responsiveness splenectomy , corticosteroid rituximab . Current trial design investigate impact genetic predisposition FcγRIIIA polymorphisms refractory ITP patient treat Eltrombopag along cytokine profile expression responder non responder . Eltrombopag small molecule thrombopoietin receptor agonist oral administration . Eltrombopag interact transmembrane domain thrombopoietin receptor ( also know cMpl ) lead increase platelet production.It specifically indicate treatment thrombocytopenia patient chronic immune ( idiopathic ) thrombocytopenic purpura ( ITP ) insufficient response corticosteroid , immunoglobulin , splenectomy . Eltrombopag supply tablet design oral administration . In Pakistan , patient ; East Asian ancestry moderate severe hepatic impairment , recommend initial dose Eltrombopag 25 mg daily . Eltrombopag adjust achieve maintain platelet count &gt; 50 x 109/L necessary reduce risk bleeding . The dose Eltrombopag exceed 75 mg daily . Methodology : 1 . Blood sample ( serum , plasma , DNA* ) collect 50 control ( treat standard immunosuppressive therapy ( IST ) first second line treatment ) 25 patient ( steroids refractory ) time enrollment trial ( pre-treatment ; 0 ) sequentially 3 6 month treatment . 2 . When marrow analysis indicate , marrow specimen also collect studied patient undergoes splenectomy part treatment , spleen specimen also collect cryopreserved . 3 . Fc gamma RIIIA V158F polymorphism assess mean allele-specific PCR and/nested PCR follow sequence verification 4 . In order validate genotype study participant ; direct sequencing SNPs do automate capillary sequencing method . 5 . Thrombopoietin ( THPO ) expression quantify treatment 0 , 3 6 month treatment real time PCR use house keep gene ( Beta Actin ) positive control refractory control subject . 6 . The sequential analysis T cell anti-platelets ( anti-GpIIbIIIa ) antibody produce B cell perform treatment mean flow cytometry order characterize T cell ( TH1 , TH2 , TH17 , TFH , Tregs subset ) B cell ( CD19+ represent B cell regulator ) . 7 . Immune cell express cytokine subject wild type mutate genotype measure investigate correlation platelet recovery responder non responder use Human Thrombopoietin Luminex performance Assay ( R &amp; D system Inc. ; Bead-based multiplex assay Luminex® platform ) . 8 . To find association Fc V158F genotypic distribution THPO cytokine expression THPO agonists responder nonresponders ; statistical analysis perform use statistical program SPSS ( Version 23.0 ) .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Steroid refractory ITP define accord recent consensual criterion ( Rodeghiero F et al . Blood 2009 ) , Informed consent . The control patient include ; Age sex match control Control ITP group ( treat standard immunosuppressive therapy ( IST ) first second line treatment ) Secondary ITP Other hematological malignant disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ITP</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Steroid refractory</keyword>
	<keyword>Fc Receptor</keyword>
</DOC>